Tracked shipping to Austria with premium packaging for just 3,99 € 

Ship to
Austria
0

My Account

  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional

menu

Select your country

Americas

Europe

Rest of the world

portada The Challenge of CMC Regulatory Compliance for Biopharmaceuticals
Type
Physical Book
Author
Publisher
Language
English
Pages
573
Format
Hardcover
Dimensions
23.4 x 15.6 x 3.3 cm
Weight
1.03 kg.
ISBN13
9783031319082
Edition No.
0004
Categories

The Challenge of CMC Regulatory Compliance for Biopharmaceuticals

John Geigert (Author) · Springer · Hardcover

The Challenge of CMC Regulatory Compliance for Biopharmaceuticals - Geigert, John

Cheaper New Book Imported to Austria
Delivery: 15 Jul - 22 Jul Shipping: 12 to 16 business days.
214,69 €
Faster New Book Imported to Austria
Delivery: 03 Jul - 07 Jul Shipping: 4 to 5 business days.
221,67 €
Import costs and 10% VAT included in the price ✅
214,69 €

Choose the list to add your product or create one New List

Go to My Wishlists
Calculate shipping cost

Synopsis "The Challenge of CMC Regulatory Compliance for Biopharmaceuticals"

Each year for the past three years, there have been about 50 new molecular medicines approved by the United States Food & Drug Administration (FDA), of which approximately 25% were new biopharmaceuticals. Over 200 recombinant proteins, monoclonal antibodies, antibody drug conjugates, fusion proteins, and Fab fragments are now in the marketplace in both the United States of America (USA) and European Union (EU). There are also now over 60 biosimilars available for all major classes of recombinant proteins and monoclonal antibodies. In addition, gene therapies using genetically engineered viruses and genetically engineered cells are now in the marketplace, and continually growing. This degree of change is reflected in the over 400 CMC regulatory compliance references listed in this book that were either issued or updated since the release of the third edition. Deficiencies in biopharmaceutical CMC regulatory compliance rarely result in termination of a product, but in can readily cause months if not years of delay in initiating clinical trials, or advancing clinical development stages, or even market approval. In summary, this book: Updates real-world CMC deficiency examples with current examples;Addresses current FDA and EMA requirements and expectations for CMC regulatory compliance;Now includes CMC regulatory compliance for the new gene-based biopharmaceuticals.

Customers reviews

More customer reviews
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)

Frequently Asked Questions about the Book

Is the book original?

All books in our catalog are Original.

In what language is the book written?

The book is written in English.

What is the format of this book?

The binding of this edition is Hardcover.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews